MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202617029607 A) filed by Universit Laval on March 12, 2026, for Irreversible 17beta-Hsd1 Inhibitors.
Inventors include Maltais, Ren; and Poirier, Donald.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: Compounds of formula (I), pharmaceutical compositions thereof, and kits thereof, are disclosed wherein A1 is C(O) or CHRz1 with Rz1 being OH, amine, imine, halogen, (C1-C5)alkoxy, OC(O)(C1-C5)alkyl, or OSO2-amine; A2 is CH2 or O; R1 is hydrogen, (C1-C5)alkyl optionally substituted with one or more Z substituents, (C1-C5)alkoxy optionally substituted with one or more Z substituents, (C2-C5)alkenyl optionally substituted with one or more Z substituents, (C2-C5)alkynyl optionally substituted with one or more Z substituents, (C3-C8)cycloalkyl, aryl, or heteroaryl; Z is halogen, OH, (C1-C5)alkyl, (C1-C5)haloalkyl, (C1-C5)alkoxy, (C1- C5)haloalkoxy, or amine; R2 is a heterocyclic aromatic ring having 5, 6 or 7 members having at least one N, S and/or O; R3 is a (C1-C5)alkyl substituted with one or more Br, Br76; I, I123, I124, or I131; m is an integer from 0 to 2; n is an integer from 0 to 2; and p is an integer from 0 to 5. Compounds of Formula I are inhibitors of 17ß-Hydroxysteroid dehydrogenase type 1 (17ß-HSD1) and are for use in the treatment or prevention of steroid hormone dependent disease, such as breast cancer, lung cancer, prostate carcinoma, ovarian cancer, uterine cancer, endometrial cancer and endometrial hyperplasia.
Disclaimer: Curated by HT Syndication.
